Re: “Harmonizing the Nomenclature for Therapeutic Aerosol Particle Size: A Proposal” by Hillyer et al. (J Aerosol Med Pulm Drug Deliv. 2018 [31(2):111–113];DOI: 10/1089/jamp.2017.1396)
Restricted accessLetterFirst published online August, 2018
Re: “Harmonizing the Nomenclature for Therapeutic Aerosol Particle Size: A Proposal” by Hillyer et al. (J Aerosol Med Pulm Drug Deliv. 2018 [31(2):111–113];DOI: 10/1089/jamp.2017.1396)
HillyerEV, PriceDB, ChrystynH, MartinRJ, IsraelE, van AalderenWMC, PapiA, UsmaniOS, and RocheN: Harmonizing the nomenclature for therapeutic aerosol particle size: A proposal. J Aerosol Med Pulmon Deliv. 2018; 31:111–113.
2.
ForbesB, BäckmanP, ChristopherD, DolovichM, LiBV, and MorganB: In vitro testing for orally inhaled products: Developments in science-based regulatory approaches. AAPS PharmSciTech. 2015; 17:837–852.
3.
TenaAF, and ClaraPC: Deposition of inhaled particles in the lungs. Arch Bronchoneumonol. 2012; 48:240–246.
4.
LeachCL, DavidsonPJ, HasselquistBE, BoudreauRJ: Influence of particle size and patient dosing technique on lung deposition of HFA-beclomethasone from a metered dose inhaler. J Aerosol Med. 2005; 18:379–385.
5.
DolovichM, and LabirisR: Imaging drug delivery and drug responses in the lung. Proc Am Thorac Soc. 2004; 1:329–337.
6.
MitchellJP, and NagelMW: Cascade impactors for the size characterization of aerosols from medical inhalers: Their uses and limitations. J Aerosol Med. 2003; 16:341–377.
7.
MarpleVA, LiuBYH, and WhitbyKT: On the flow fields of inertial impactors. J Fluids Eng. 1974; 96:394–400.
8.
MarpleVA, and RubowKL: Theory and design guidelines. In: LodgeJ and ChanT, (eds). Cascade Impactor Sampling and Design. AIHA, Akron, OH; pp.79–101, 1986.
9.
MarpleVA, RobertsDL, RomayFJ, MillerNC, TrumanKG, Van OortM, OlssonB, HolroydMJ, MitchellJP, HochrainerD: Next generation pharmaceutical impactor (a new impactor for pharmaceutical inhaler testing). Part 1: Design. J Aerosol Med. 2003; 16:283–299.
10.
NewmanS: Aerosol properties and deposition principles. In: NewmanS, (ed). Respiratory Drug Delivery: Essential Theory and Practice. Respiratory Drug Delivery Online, Richmond, VA; pp. 29–58, 2009.
11.
Annals of the International Commission on Radiological Protection: Human Respiratory Tract Model for Radiological Protection. Pergamon Press (Elsevier Science), Tarrytown, NY, 1994.
12.
DunbarC, and MitchellJ: Analysis of cascade impactor mass distributions. J Aerosol Med. 2005; 18:439–451.
13.
DiFioreJW, and WilsonJM: Lung development. Semin Pediatr Surg. 1994; 3:221–232.
14.
FokTF, MonkmanS, DolovichM, GrayS, CoatesG, PaesB, RashidF, NewhouseM, KirpalaniH: Efficiency of aerosol medication delivery from a metered dose inhaler versus jet nebulizer in infants with bronchopulmonary dysplasia. Pediatr Pulmonol. 1996; 21:301–309.
15.
LaubeB, LinksJM, LaFranceND, WagnerHM, and RosensteinBJ: Homogeneity of bronchopulmonary distribution of 99mTc aerosol in normal subjects and cystic fibrosis patients. Chest. 1989; 95:822–830.
16.
RubinBK: Aerosol medications for treatment of mucus clearance disorders. Respir Care. 2015; 60:825–832.
17.
CoxsonHO. Leipsic J, ParragaG, Sin DD: Using pulmonary imaging to move chronic obstructive pulmonary disease beyond FEV1. Am J Respir Crit Care Med. 2014; 190:135–144.
18.
JamesAL, and WenzelS: Clinical relevance of airway remodeling in airway diseases. Eur Respir J. 2007; 30:134–155.
19.
MansourHM, RheeYS, and WuX: Nanomedicine in pulmonary delivery. Int J Nanomedicine. 2009; 4:299–319.
20.
BakandS, HayesA, and DechsakulthornF: Nanoparticles: A review of particle toxicology following inhalation exposure. Inhalation Toxicology. 2012; 24.2:125–135.
21.
WeersJ: Regional deposition of particles within the respiratory tract should be linked to impaction parameter, not aerodynamic size. J Aerosol Med Pulmon Drug Deliv. 2018; 31:116–118.
22.
MartinAR, and FinlayWH: A general algebraic equation for predicting total respiratory tract deposition of micrometer-sized aerosol particles in humans. J Aerosol Sci. 2007; 38:246–253.
23.
European Directorate for Quality in Medicines and Healthcare (EDQM): European Pharmacopeia 9.0, Monograph 2.9.18. Preparations for Inhalation: Aerodynamic Assessment of Fine Particles. EDQM, Strasburg, France, 2017.
